Balance Sheet
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Gsk (GLAXF) Invested Capital (2016 - 2025)

Gsk has reported Invested Capital over the past 11 years, most recently at $71.4 billion for Q4 2025.

  • Quarterly results put Invested Capital at $71.4 billion for Q4 2025, up 10.28% from a year ago — trailing twelve months through Dec 2025 was $71.4 billion (up 10.28% YoY), and the annual figure for FY2025 was $71.4 billion, up 10.28%.
  • Invested Capital for Q4 2025 was $71.4 billion at Gsk, up from $64.7 billion in the prior quarter.
  • Over the last five years, Invested Capital for GLAXF hit a ceiling of $71.4 billion in Q4 2025 and a floor of $32.6 billion in Q4 2022.
  • Median Invested Capital over the past 5 years was $47.0 billion (2021), compared with a mean of $50.2 billion.
  • Biggest five-year swings in Invested Capital: crashed 30.69% in 2022 and later soared 83.66% in 2024.
  • Gsk's Invested Capital stood at $47.0 billion in 2021, then crashed by 30.69% to $32.6 billion in 2022, then increased by 8.07% to $35.2 billion in 2023, then surged by 83.66% to $64.7 billion in 2024, then increased by 10.28% to $71.4 billion in 2025.
  • The last three reported values for Invested Capital were $71.4 billion (Q4 2025), $64.7 billion (Q4 2024), and $35.2 billion (Q4 2023) per Business Quant data.